Marshall Wace
ACAD icon

Marshall Wace’s Acadia Pharmaceuticals ACAD Stock Holding History

Marshall Wace’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Sell
76,187
-417,192
-85% -$9.97M ﹤0.01% 1875
2025
Q4 		$13.2M Sell
493,379
-1,865,502
-79% -$44.6M 0.01% 773
2025
Q3 		$50.3M Buy
2,358,881
+389,170
+20% +$9.2M 0.05% 314
2025
Q2 		$42.5M Buy
1,969,711
+1,639,315
+496% +$30.5M 0.05% 338
2025
Q1 		$5.49M Sell
330,396
-663,197
-67% -$12M 0.01% 1018
2024
Q4 		$18.2M Sell
993,593
-195,019
-16% -$3.15M 0.02% 578
2024
Q3 		$18.3M Sell
1,188,612
-1,585,741
-57% -$26.5M 0.02% 536
2024
Q2 		$45.1M Buy
2,774,353
+2,251,940
+431% +$36.3M 0.06% 285
2024
Q1 		$9.66M Buy
+522,413
New +$12.9M 0.01% 758
2023
Q4 		– Sell
-941,755
Closed -$19.6M – 2114
2023
Q3 		$19.6M Buy
941,755
+916,903
+3,689% +$24.9M 0.04% 446
2023
Q2 		$595K Buy
+24,852
New +$552K ﹤0.01% 1924
2022
Q2 		– Sell
-532,557
Closed -$12.9M – 3366
2022
Q1 		$12.9M Buy
+532,557
New +$12.9M 0.02% 704
2021
Q1 		– Sell
-848,679
Closed -$45.4M – 2412
2020
Q4 		$45.4M Sell
848,679
-285,133
-25% -$14.2M 0.25% 85
2020
Q3 		$46.8M Buy
1,133,812
+933,686
+467% +$40.3M 0.3% 73
2020
Q2 		$9.7M Buy
+200,126
New +$9.61M 0.07% 293
2016
Q2 		– Sell
-37,174
Closed -$1.04M – 965
2016
Q1 		$1.04M Buy
+37,174
New +$811K 0.01% 700
2015
Q2 		– Sell
-22,686
Closed -$739K – 879
2015
Q1 		$739K Buy
+22,686
New +$780K 0.01% 622

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Marshall Wace's ACAD Position: Q1 2026 in Review

Marshall Wace reduced its Acadia Pharmaceuticals (ACAD) stake by 85% in Q1 2026, selling an estimated $9.97M and leaving 76,187 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Marshall Wace first reported a position in ACAD in Q1 2015 and has held it in 17 quarters since. The position peaked at $50.3M in Q3 2025. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Marshall Wace held 76,187 shares of Acadia Pharmaceuticals worth $1.7M as of Q1 2026.
  • Marshall Wace sold 417,192 Acadia Pharmaceuticals shares in Q1 2026, an estimated $9.97M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1875 holding.
  • Marshall Wace first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 17 quarters since.
  • Marshall Wace's Acadia Pharmaceuticals position peaked at $50.3M in Q3 2025.
  • 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.